After Needham and Mizuho Securities gave Zogenix (NASDAQ: ZGNX) a Buy rating last month, the company received another Buy, this time from Stifel Nicolaus. Analyst Paul Matteis maintained a Buy rating on Zogenix today and set a price target of $70.00. The company’s shares closed last Monday at $44.08.
According to TipRanks.com, Matteis is a 5-star analyst with an average return of 19.5% and a 53.7% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, BioMarin Pharmaceutical, and ACADIA Pharmaceuticals.
Zogenix has an analyst consensus of Strong Buy, with a price target consensus of $63.71, a 45.0% upside from current levels. In a report issued on October 29, Mizuho Securities also maintained a Buy rating on the stock with a $65.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $56.50 and a one-year low of $33.43. Currently, Zogenix has an average volume of 442.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zogenix, Inc. is a pharmaceutical compan. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday.
